Molecular Differences in Mucoepidermoid Carcinoma and Adenoid Cystic Carcinoma of the Major Salivary Glands

Gibbons, M. David; Manne, Upender; Carroll, William R.; Peters, Glenn E.; Weiss, Heidi L.; Grizzle, William E.

doi:10.1097/00005537-200108000-00011

Cited by 78 publications

(62 citation statements)

References 31 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The overexpression of EGFR is generally believed to be common in salivary gland carcinoma, although the incidence of positive EGFR staining was found to be 25% (2/8) in an earlier study with a small sample size (20). Gibbons et al found 17 out of 22 (77%) mucoepidermoid carcinoma cases with EGFR overexpression (21). We reported on a series of 46 patients of mucoepidermoid carcinoma.…”

Section: Discussionmentioning

confidence: 71%

“…According to the limited literature, the overexpression of EGFR was reported to be 25 and 77% respectively (20,21). EGFR-targeted drugs are now commercially available, including small-molecule tyrosine kinase inhibitors (e.g.…”

Section: Discussionmentioning

confidence: 99%

“…The knowledge of EGFR levels within mucoepidermoid carcinoma was limited and the reported frequencies of EGFR overexpression varied greatly (20,21). HER2 overexpression occurs in 0 to 38% of mucoepidermoid carcinoma (22)(23)(24)(25)(26)(27)(28).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Epidermal growth factor receptor and human epidermal growth receptor 2 expression in parotid mucoepidermoid carcinoma: Possible implications for targeted therapy

Shang

Shui²,

Sheng³

et al. 2008

Oncol Rep

View full text Add to dashboard Cite

Abstract. The expression of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) was analyzed in immunohistochemical preparations from 46 primary parotid mucoepidermoid carcinomas (MEC). For the cases with lymph node metastases, the receptor expressions were investigated in parallel samples, primary tumour and metastasis, from each patient (n=11). The goal was to evaluate whether any of these receptors are suitable as a target for radionuclide-based imaging and therapy. The HercepTest scoring was used for the analysis of both HER2 and EGFR expression (0, 1+, 2+ or 3+). EGFR overexpression (2+/3+) was found in 67.4% (31/46) of the primary tumours. Out of the 11 cases with evaluated paired samples, EGFR overexpression was observed in 81.8% (9/11) of the primary tumours and 72.7% (8/11) of the corresponding lymph node metastases. There was only one patient who had EGFR overexpression in the primary tumours which changed to negative in the lymph node metastases but no changes occurred reciprocally. The HER2 overexpression was only found in 4.3% (2/46) of the primary mucoepidermoid carcinoma and none of the lymph node metastases (0/11). EGFR and HER2 stainings were mainly found in the cell membranes. It was concluded that the majority of parotid mucoepidermoid carcinomas express EGFR strongly in their cell membranes and that lymph node metastases generally express EGFR to approximately the same extent as in the primary tumours. The stability in the EGFR expression is encouraging in the effort to develop radionuclide-based EGFR imaging agents. It is also possible that EGFR targeting agents (e.g. Iressa, Tarceva, Erbitux or radiolabelled antibodies) can be applied for the therapy of mucoepidermoid carcinoma.

show abstract

Section: Discussionmentioning

confidence: 71%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Epidermal growth factor receptor and human epidermal growth receptor 2 expression in parotid mucoepidermoid carcinoma: Possible implications for targeted therapy

Shang

Shui²,

Sheng³

et al. 2008

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…Neuroendocrine tumors of the lung, including small cell carcinomas, usually do not express EGFR 13 and are virtually always negative for EGFR mutation. 14 Although EGFR expression has been reported in salivary gland carcinomas of the head and neck, [15][16][17][18] little is known about EGFR mutation, amplification, and expression in salivary gland-type tumors of the lung.…”

mentioning

confidence: 99%

Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study

Macarenco¹,

Uphoff

Gilmer

et al. 2008

Modern Pathology

View full text Add to dashboard Cite

Salivary gland-type lung carcinomas are uncommon neoplasms of the lung, the two most common being adenoid cystic carcinoma and mucoepidermoid carcinoma. Although they usually have an indolent behavior, adenoid cystic carcinomas can be more aggressive, with 5-year survival as low as 55%. Unfortunately, these tumors do not respond well to chemotherapy. In contrast to the most common subtypes of lung carcinomas, epidermal growth factor receptor studies have not been carried out in this group of tumors. Herein we report a series of 24 cases (12 adenoid cystic and 12 mucoepidermoid carcinomas) tested for epidermal growth factor receptor protein expression, epidermal growth factor receptor gene copy gains, and epidermal growth factor receptor gene mutational status, through immunohistochemistry, fluorescence in situ hybridization, and sequencing of the exons 18-21, respectively. Overall, 91 and 92% of the adenoid cystic carcinomas and mucoepidermoid carcinomas expressed epidermal growth factor receptor protein. Chromosome 7 polysomy occurred in 25% of the cases (four adenoid cystic carcinomas and two mucoepidermoid carcinomas). No epidermal growth factor receptor gene amplification was detected and no mutation was found in exons 18-21 of the epidermal growth factor receptor gene. Immunoexpression of epidermal growth factor receptor in salivary gland-type lung carcinomas is not related to epidermal growth factor receptor gene copy number or mutational status. Keywords: salivary gland-type lung carcinoma; adenoid cystic carcinoma; mucoepidermoid carcinoma; epidermal growth factor receptor; immunohistochemistry; FISH Salivary gland-type lung carcinomas are uncommon, representing less than 1% of all lung tumors. Adenoid cystic carcinoma and mucoepidermoid carcinoma are the two most common subtypes. 1,2 Salivary gland-type lung carcinomas are generally reported as having a good prognosis. Indeed, mucoepidermoid carcinoma usually presents as a localized disease that can be completely resected with surgery and the reported 5-and 10-year survivals rates are both 87%. 3 However, patients with mucoepidermoid carcinomas can develop local or distant metastasis, which are typically unresponsive to conventional chemotherapy and radiation. In contrast, adenoid cystic carcinoma tends to present at a higher stage, is often unresectable, or, if resected, often has positive margins and subsequent local recurrences. The prognosis is also poorer with recent reported 5-and 10-year survivals of 55 and 39%, respectively. 3 As with mucoepidermoid carcinoma, the survival does not appear to be affected by traditional chemotherapy and radiation. Therefore, there appears to be a potential use for targeted novel therapies in the care of these patients.

show abstract

“…There have been suggestions that the overexpression of c-erbB-2 on salivary gland tumors is related with histogenesis of these lesions (Glisson et al, 2004;Rivière et al, 1991;Gibbons et al, 2001, Rosa et al, 1997. MEC is composed of varying proportions of mucous, epidermoid, columnar, intermediate and clear cells (Auclair et al) and is though to arise from the salivary excretory duct (Ellis et al).…”

Section: Discussionmentioning

confidence: 99%

Intraoral Mucoepidermoid Carcinoma of Salivary Glands: Lack of Association Among Clinicopathological Features and Immunoexpression of c-erbB-2 in 29 Cases

Bernardes¹,

Ramos-Jorge²,

Carmo³

et al. 2008

Int. J. Morphol.

View full text Add to dashboard Cite

SUMMARY:The association among clinicopathological features and c-erbB-2 oncoprotein expression was evaluated in twentynine cases of intra-oral mucoepidermoid carcinoma (MEC). MEC was prevalent in the female gender (79.3%), tumors were more frequent in ages between 21 and 40 years (48.3%), and the palate was the most commonly affected site (72.4%). Microscopically, 27 cases (93.1%) were classified as low grade of malignancy. The c-erbB-2 expression was considered positive in 9 (31%) cases and no significant association (p>0.05) was found among protein expression and gender nor between patient age and site or histological grade of the lesion. c-erbB-2 expression in MEC may reflect intrisinc biologic properties of salivary gland neoplasms and may be linked to histogenesis and cellular differentiaton.

show abstract

Molecular Differences in Mucoepidermoid Carcinoma and Adenoid Cystic Carcinoma of the Major Salivary Glands

Cited by 78 publications

References 31 publications

Epidermal growth factor receptor and human epidermal growth receptor 2 expression in parotid mucoepidermoid carcinoma: Possible implications for targeted therapy

Epidermal growth factor receptor and human epidermal growth receptor 2 expression in parotid mucoepidermoid carcinoma: Possible implications for targeted therapy

Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study

Intraoral Mucoepidermoid Carcinoma of Salivary Glands: Lack of Association Among Clinicopathological Features and Immunoexpression of c-erbB-2 in 29 Cases

Contact Info

Product

Resources

About